Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:
- Tanezumab (codenamed RN624),[1][2] a monoclonal antibody against nerve growth factor for the treatment of pain
- Ponezumab (codenamed RN1219),[3] a monoclonal antibody against beta amyloid for the treatment of Alzheimer's disease
- Fremanezumab (codenamed TEV-48125, RN307 and LBR-101),[4][5][6] a monoclonal antibody against calcitonin gene-related peptide for the treatment of migraines
- Bococizumab (codenamed RN316),[7] a monoclonal antibody against PCSK9 designed to reduce LDL cholesterol
- RN6G, a monoclonal antibody against beta amyloid for the treatment of geographic atrophy in age-related macular degeneration[8]
- RN909, a monoclonal antibody antagonist of the glucagon receptor for type 2 diabetes (T2DM)[9]
- REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer[10]
- PF-04518600, a monoclonal antibody targeting OX40 to enhance T cell functions and inhibit tumor growth[11]
Rinat was founded in 2001 by Arnon Rosenthal,[12][13] who was also Rinat's president, chief scientific office and board director, and Patrick Lynn,[14] following a broad licensing agreement with Genentech,[15] and was acquired by Pfizer in 2006 for approximately $500M.[16][17] Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco.[18]
References
edit- ^ Vastag, Brian. "Monoclonals expand into neural disorders". Nature.
- ^ Lane, Nancy E.; et al. (2010). "Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee". New England Journal of Medicine. 363 (16). The New England Journal of Medicine: 1521–1531. doi:10.1056/NEJMoa0901510. PMC 6896791. PMID 20942668. S2CID 16950684.
- ^ "Ponezumab". ALZForum.
- ^ "Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio". Business Wire/Nasdaq.
- ^ Carroll, John. "In biotech trifecta, startup lassos $31M, a CEO and a lead drug from Pfizer". FierceBiotech.
- ^ Leuty, Ron. "Migraine drug developer Labrys targeted by Teva in $825 million deal". San Francisco Business Times.
- ^ Berkrot, Bill; Beasley, Deena. "Experimental Pfizer cholesterol drug promising in study". Reuters.
- ^ "An Investigational Therapy for Geographic Atrophy in Age-Related Macular Degeneration".
- ^ Gumbiner, Barry; Esteves, Brooke; Dell, Vanessa; Joh, Tenshang; Garzone, Pamela D.; Forgie, Alison; Udata, Chandrasekhar (2018). "Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes". Endocrine. 62 (2): 371–380. doi:10.1007/s12020-018-1597-1. PMID 30203123. S2CID 52184370.
- ^ "REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer".
- ^ "FIH study of an OX40 agonist mAb PF-04518600 in adult patients with select advanced solid tumors".
- ^ "Arnon Rosenthal Ph.D. - Executive Profile". Bloomberg Businessweek. Archived from the original on October 26, 2014.
- ^ Leuty, Ron. "Alector snags funding in founder's latest attack on Alzheimer's". San Francisco Business Times.
- ^ "Patrick G. Lynn - Executive Profile". Bloomberg Businessweek. Archived from the original on October 26, 2014.
- ^ "Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain". Genentech.
- ^ Pollack, Andrew. "Pfizer to Buy Rinat, a Biotechnology Drug Maker". New York Times.
- ^ "Pfizer to Expand Neuroscience Research with Acquisition of Biotech Company Rinat Neuroscience disorders". Pfizer. Archived from the original on 2015-09-24.
- ^ "Rinat". Pfizer. Archived from the original on 2014-09-01.
This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |